Health Economics›Liposarcoma›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Liposarcoma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trabectedin monotherapy Variant #01	—	R 103 351	21d	—	13.7 mo	2	R 206 702 PFS proxy	1
Eribulin monotherapy Variant #01	—	R 22 427	21d	—	15.6 mo	2	R 44 854 PFS proxy	1
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	—	10.8 mo	2	R 5 217 PFS proxy	2
Placebo Partial	—	—	—	2.1 mo	—	—	—	1
Selinexor monotherapy Variant #01 Partial	—	—	7d	2.8 mo	—	2	—	1

5 of 5 regimens shown